Table 1.
Patient characteristics
| Case | Control | p | |
|---|---|---|---|
| n | 55 | 123 | |
| Center = Rotterdam (%) | 22 (40.0) | 54 (43.9) | 0.747 |
| Age, years (median [IQR]) | 63 [56, 68] | 57 [46, 66] | 0.073 |
| Male gender (%) | 34 (61.8) | 66 (53.7) | 0.395 |
| Weight, kg (median [IQR]) | 70 [60, 84] | 70 [62, 85] | 0.910 |
| Underlying disease (%) | 0.355 | ||
| Pulmonary disease | 22 (40.0) | 59 (52.2) | |
| Hematologic malignancy | 9 (16.4) | 10 (8.8) | |
| Heart disease | 4 (7.3) | 10 (8.8) | |
| Liver disease | 3 (5.5) | 5 (4.4) | |
| Gastrointestinal disease | 3 (5.5) | 2 (1.8) | |
| Other malignancy | 2 (3.6) | 9 (8.0) | |
| Other | 12 (21.8) | 18 (15.9) | |
| Neutropenia (%) | 8 (17.0) | 7 (5.7) | 0.094 |
| Influenza (%) | 17 (30.9) | 47 (38.2) | 0.442 |
| COPD (%) | 6 (10.9) | 15 (12.2) | 1.000 |
| Positive culture (%) | 28 (50.9) | ||
| Positive microscopy (%) | 4 (7.3) | ||
| BALf GM (median [IQR]) | 4.80 [2.73, 5.68] |
IQR interquartile range, BALf GM bronchoalveolar lavage fluid galactomannan, COPD chronic obstructive pulmonary disease